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Abstract
In order to isolate the unidentified autoantigens in autoimmune diabetes, a human pancreatic islet cDNA library was
constructed and screened with the sera from the diabetic patients. From the library screening, one clone (DRS-1) that
strongly reacted with the sera was isolated. Subsequent sequence analysis revealed that the clone was a novel cDNA related
to the diazepam binding inhibitor. DRS-1 was expressed in most tissues including liver, lung, tonsil, and thymus, in addition
to pancreatic islets. DRS-1 was in vitro translated and the recombinant DRS-1 protein was expressed in Escherichia coli and
purified. The size of the in vitro translated or bacterially expressed DRS-1 protein was in agreement with the conceptually
translated polypeptide of DRS-1 cDNA. Further studies are required to test whether or not DRS-1 is a new autoantigen in
autoimmune diabetes. ß 1999 Elsevier Science B.V. All rights reserved.
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In autoimmune diabetes, pancreatic islets are de-
stroyed by the chronic autoimmune responses to islet
cells and the autoantibodies to various islet antigens
are detected in a large panel of diabetic sera [1,2].
The identi¢ed islet autoantigens include glutamic
acid decarboxylase (GAD), IA-2, insulin, and car-
boxypeptidase-H. Although the pathological implica-
tions of the autoantibodies to these antigens are not
well elucidated, the presence of the autoantibodies in
the patients’ sera has been used as a diagnostic
marker for autoimmune diabetes. Characterization
of the autoantigens responsible for the islet destruc-
tion will greatly enhance our understanding of the
pathogenic mechanism of the autoimmune diabetes.
Biochemical as well as molecular approaches have
been used for the identi¢cation and characterization
of some of these diabetic autoantigens [3^5]. Current
work was initially undertaken to isolate the uniden-
ti¢ed autoantigens in autoimmune diabetes using a
molecular approach. We constructed a cDNA library
of human pancreatic islets and screened the library
with diabetic patient sera. From screening with
pooled sera of 10 patients, we isolated three clones
that strongly reacted with the patients’ sera. Subse-
quent sequence determination revealed that two of
these cDNA clones were derived from the same
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mRNA. The deduced amino acid sequence of these
cDNA clones was related to the diazepam binding
inhibitor (DBI), thus the cDNA clone was named
DRS-1 (for DBI-related sequence-1). Further studies
will be necessary to determine whether or not DRS-1
is a new autoantigen in autoimmune diabetes.
To construct a human pancreatic islet cDNA li-
brary, total RNA was isolated from human pancre-
Fig. 1. Nucleotide and predicted amino acid sequences of human DRS-1 cDNA. The box indicates the conserved acyl CoA binding
motif. The asterisk indicates the presumed termination codon. Poly(A) signal is underlined. The nucleotide sequence shown here has
been deposited in the GenBank with the accession number of AF069301.
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atic islets obtained from the brain-dead donors by
guanidinium thiocyanate^acid phenol^chloroform
extraction as previously described [6]. Poly(A)
RNA was puri¢ed by the selection with biotinylated
oligo(dT) and streptavidin coupled with paramag-
netic particles (Promega, Madison, WI). The cDNA
library was constructed using a ZAP Express-cDNA
synthesis kit (Stratagene, La Jolla, CA) according to
the manufacturer’s protocol. Brie£y, the ¢rst strand
cDNA was synthesized from 5 Wg of poly(A) RNA
with Moloney-murine leukemia virus reverse tran-
scriptase and XhoI-linked oligo(dT) primers in the
presence of methyl nucleotides, followed by the sec-
ond strand synthesis with RNase H and DNA
polymerase I. After the double-stranded cDNA was
blunt-ended with dNTP and T4 DNA polymerase,
the cDNA was ligated to the EcoRI linkers, then
digested with XhoI. The sephacryl column-puri¢ed
cDNA fragments were ligated into the EcoRI and
XhoI sites of the bacteriophage lambda vector arms
(ZAP-Express). The ligated vectors were packaged
using the Gigapack II Gold extracts, followed by
an ampli¢cation of the library in Escherichia coli
Sure strain to yield 5U109 plaque-forming units/ml.
To screen the human islet cDNA library, the
phage library of the total 5U105 clones was plated
on the LB agar and incubated at 42‡C for 4 h, and
then overlaid at 37‡C for 3 h with 10 mM IPTG-
impregnated nitrocellulose membranes (Schleicher
and Schuell, Dassel, Germany). Plaque lifts were ini-
tially screened with the pooled sera from 10 diabetic
patients, which were diluted 1:200 in 20 mM Tris-
HCl (pH 7.5)^150 mM NaCl (TBS) containing 1%
BSA and repeatedly preabsorbed with E. coli lysate.
After the incubation of the plaque lifts with the di-
luted sera at 25‡C for 1 h, bound antibody was de-
tected by sequential incubations at 25‡C with alka-
line phosphatase-conjugated goat anti-human IgG
antibody (Dako, Carpenteria, CA), and with chro-
mogenic substrates (NBT and BCIP; Gibco-BRL,
Gaithersburg, MD). Membranes were washed three
times with TBS containing 0.05% Tween-20 after
each incubation. Three positive clones were ¢nally
isolated after the secondary and tertiary screening,
which were carried out in the same manner as the
initial screening.
For isolation and sequence analysis of the DRS-1
cDNA clone, three positive phage clones from the
library screening were subjected to in vivo excision
by ExAssist helper phage coinfection (Stratagene)
according to the manufacturer’s instructions. When
the pBK-CMV phagemids containing cDNA inserts
of three positive clones were sequenced with T3
primer using an automated sequencing system (ABI
377; PE Applied Biosystems, Foster City, CA), two
Fig. 2. Alignment of amino acid sequences of DRS-1 and DBI
of various species (A) or DRS-1 and carp ACBP/ECHM (B).
The underlined sequence indicates the conserved acyl CoA
binding motif. The asterisks denote consensus sequences. Gaps
(3) are introduced to achieve maximum homology. DRS-1
showed a 46^54% local homology to DBI of various species.
SWISS-PROT data base accession numbers of DBI sequences
cited for comparison are as follows: human DBI, P07108; por-
cine DBI, P12026; bovine DBI, P07107; mouse DBI, P31786;
rat DBI, P11030; chicken DBI, S63595; and yeast DBI,
P31787.
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clones were identical. The two identical clones were
further characterized in this study. Restriction diges-
tion of the isolated clone (DRS-1) revealed that the
insert size was V1.4 kb. Nucleotide sequence of the
insert was determined to uncover that DRS-1 codes
for polypeptide of 364 amino acid residues (Fig. 1).
Data base sequence similarity search using the
BLAST program (GCG, University of Wisconsin)
revealed that the deduced amino acid sequence of
DRS-1 is related to the human, porcine, bovine,
mouse, rat, chicken, and yeast diazepam binding in-
hibitors (DBI) (Fig. 2A). DBI is a highly conserved
protein that is widely distributed throughout phylo-
genesis [7]. DBI was ¢rst identi¢ed as a polypeptide
that has binding activity and elicits behavioral e¡ects
expected for a ligand to the benzodiazepine site [7^9].
Although it was ¢rst thought that DBI has a speci¢c
distribution in brain nuclei and is highly concen-
trated in the hypothalamus and cerebellum [10^12],
later studies demonstrated that the protein is ex-
pressed in a large number of di¡erent tissues [13].
DBI mediates various neurological actions, including
the induction of anti-anxiety by binding to the ben-
zodiazepine recognition sites associated with Q-ami-
nobutyric acid (GABAA) receptors [7]. Moreover,
DBI turned out to be identical with the acyl CoA
binding protein (ACBP), which was ¢rst puri¢ed
from bovine liver and capable of binding and induc-
ing synthesis of acyl CoA [14^17]. Sequence analysis
of DRS-1 also uncovered that the protein possessed
a conserved acyl CoA binding motif [18], suggesting
a potential acyl CoA binding activity of DRS-1 pro-
tein (Figs. 1 and 2).
DRS-1 also showed a signi¢cant sequence homol-
ogy with a cold-induced gene in the carp (ACBP/
ECHM; GenBank accession number, AF006493,
not published). ACBP/ECHM was cloned as a
cold-induced gene in the carp liver by a di¡erential
display RT-PCR. ACBP/ECHM has N-terminal se-
quence similar to the acyl CoA binding protein and
C-terminal sequence similar to the enoyl CoA hydra-
tase. Although the sequence of ACBP/ECHM cDNA
has been deposited in the GenBank, none of the
functional or structural characterizations of the
cDNA have been reported so far, except that the
expression of ACBP/ECHM may be upregulated in
the carp maintained at a low temperature. DRS-1
showed a 60% identity with ACBP/ECHM at an
amino acid sequence level (Fig. 2B). Moreover,
DRS-1 also has C-terminal sequence homologous
to the enoyl CoA hydratase. This suggests that
DRS-1 might be a human homolog of the carp
ACBP/ECHM gene. The expression of DRS-1, how-
ever, was not a¡ected by the cold shock in HeLa cells
(data not shown).
To investigate the expression of DRS-1, Northern
Fig. 3. Assessment of DRS-1 expression in di¡erent human tissues and cell lines. (A) Tissue distribution of DRS-1 was evaluated by
the Northern blot analysis. Total RNA isolated from di¡erent tissues was blotted onto the membrane, which was then probed with a
DRS-1 cDNA or human GAPDH cDNA. (B) Isolated RNA was subjected to RT-PCR with a primer set speci¢c for either DRS-1 or
human GAPDH. The PCR products were run on a 1% agarose gel, then stained with ethidium bromide. Speci¢cally ampli¢ed prod-
ucts were not obtained in the RT-PCR without reverse transcriptase (data not shown).
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blot analysis of RNA from di¡erent human tissues
was carried out (Fig. 3A). For the Northern blot
analysis, isolated total RNA (20 Wg per sample)
was electrophoresed in a 1.0% agarose gel containing
0.7% formaldehyde, 20 mM 3-(N-morpholino) pro-
panesulfonic acid (MOPS), 5 mM sodium acetate,
and 1 mM EDTA. RNA was transferred to the Ny-
tran membrane (Schleicher and Schuell, Keene, NH).
After a UV crosslinking, the membranes were hybri-
dized with a cDNA probe (106 cpm/ml) prepared by
digesting a pBK-CMV phagemid harboring the hu-
man DRS-1 cDNA with EcoRI and XhoI to liberate
a 1.4-kb insert. The membranes were then washed at
65‡C, dried, and exposed to X-ray ¢lms. Human
DRS-1 cDNA probe speci¢cally hybridized with
V1.4-kb band in most tissues, including liver, lung,
tonsil, thymus, and pancreatic islets, which suggests a
ubiquitous expression of the DRS-1 gene (Fig. 3A).
DRS-1 was most strongly expressed in liver. In brain
and muscle, however, a very low level of expression
was detected upon a prolonged exposure (data not
shown). The DRS-1 gene was transcribed in most
tissues as a single major mRNA species with a size
that correlated with our cloned cDNA. Di¡erences in
the mobility of DRS-1 bands among di¡erent tissues
were due to smiling in the gel during electrophoresis
as demonstrated by the reprobing with GAPDH, in
which the same mobility pattern was observed. The
expression of DRS-1 in human cell lines (HeLa and
Jurkat) and pancreatic islets was also assessed by
RT-PCR (Fig. 3B). A speci¢cally ampli¢ed product
(480 bp) was detected in the HeLa and Jurkat cell
lines as well as independently isolated pancreatic is-
lets. This supported the ubiquitous expression of the
DRS-1 gene. For RT-PCR, isolated RNA was sub-
jected to the ¢rst strand synthesis reaction using a
Superscript reverse transcriptase and oligo(dT) prim-
ers (Gibco-BRL). An aliquot of this reaction was
ampli¢ed in the presence of a primer set speci¢c for
DRS-1, dNTP, and Taq DNA polymerase (Promega,
Madison, WI). PCR was done for 25 cycles at 60‡C
annealing temperature. Nucleotide sequences of the
forward and reverse primers used in PCR were
5P-CAA AGA TCA TGT TCA ACC GGC-3P and
5P-CCT CTC CCG CTG TTA ACT TC-3P, respec-
tively.
In order to carry out in vitro translation of DRS-
1, in vivo excised pBK-CMV phagemids harboring
DRS-1 cDNA were linearized by digesting with
XhoI. Linearized cDNA was gel-puri¢ed and used
as a template in the coupled transcription and trans-
lation reaction using T3 RNA polymerase,
[35S]methionine, and TNT Coupled Reticulocyte Ly-
sate Systems (Promega). When the translated pro-
teins were analyzed by the SDS-PAGE and autora-
diography, two major bands of V36 kDa and V40
kDa were detected (Fig. 4). The size of the higher
molecular weight band (V40 kDa) correlated with
Fig. 5. Expression and puri¢cation of recombinant DRS-1 pro-
tein. (A) BL21(DE3) was transformed with pET28 expression
vector harboring DRS-1 cDNA, followed by IPTG induction.
IPTG (+) and IPTG (3) indicate transformed E. coli cells cul-
tured with or without IPTG for 0^2 h, respectively. The expres-
sion of recombinant DRS-1 protein was evaluated by Western
blot with anti-T7WTag antibody, followed by chemiluminescent
detection. The arrow indicates a recombinant DRS-1 protein of
V47 kDa tagged with T7 epitopes. Lower bands appear to be
a protein that crossreacts with the antibody used. (B) Recombi-
nant DRS-1 protein was puri¢ed using the Ni-NTA column.
Puri¢ed protein was analyzed by a 10% SDS-PAGE and Coo-
massie blue staining.
Fig. 4. In vitro translation of DRS-1. DRS-1 was in vitro trans-
lated and analyzed by 12% SDS-PAGE followed by autoradiog-
raphy. The arrow indicates the presumed DRS-1 protein of
V40 kDa.
BBADIS 60073 11-5-99
K. Suk et al. / Biochimica et Biophysica Acta 1454 (1999) 126^131130
that of the conceptually translated polypeptide of
DRS-1 cDNA. A lower molecular weight band
(V36 kDa) appears to be a translated product whose
translation was initiated from an internal ATG co-
don.
Recombinant DRS-1 protein was produced by us-
ing a prokaryotic expression vector system. A full-
length DRS-1 cDNA was cloned into pET28 expres-
sion vectors with a compatible reading frame (Nova-
gen, Madison, WI). Automatic nucleotide sequencing
using a commercial kit (ABI 377, PE Applied Bio-
systems) was carried out to con¢rm the correct read-
ing frame of the ligated plasmid. BL21(DE3), an E.
coli lysogen expressing T7 polymerase, was trans-
formed with the resulting plasmid. The expression
of DRS-1 protein was evaluated by Western blot
analysis using the horseradish peroxidase-conjugated
anti-T7WTag antibody (Novagen) (Fig. 5A). Ex-
pressed recombinant DRS-1 protein was puri¢ed us-
ing the Ni-NTA column (InVitrogen, San Diego,
CA) (Fig. 5B).
In the present work, we report the isolation of a
novel cDNA related to DBI from human pancreatic
islets. DBI has been previously shown to inhibit
glucose-stimulated insulin release from pancreatic is-
let L cells [19,20]. Since the novel clone, DRS-1,
shows a signi¢cant sequence homology to DBI, two
proteins may exert similar e¡ects on L cells. Thus, if
DRS-1 indeed a¡ects L cell insulin secretion, the ex-
pression of DRS-1 in pancreatic islets may have an
implication in the pathogenesis of autoimmune dia-
betes.
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